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Pre-transplant MRD level is highly predictive of outcome, thresholds of 200 copies / 105 ABL 
in PB and 1000 copies in BM are discriminatory. 
 
Relapse in patients with pre-transplant MRD positivity below these levels is largely restricted 




Relapse remains the most common cause of treatment failure for patients with acute 
myeloid leukaemia (AML) who undergo allogeneic stem cell transplantation (alloSCT) and 
carries a grave prognosis. Multiple studies have identified the presence of measurable 
residual disease (MRD) assessed by flow cytometry (FCM) prior to alloSCT as a strong 
predictor of relapse, but it is not clear how these findings apply to patients who test positive 
in molecular MRD assays which have far greater sensitivity. 
 
We analysed pre-transplant blood and bone marrow samples by reverse-transcription 
polymerase chain reaction (RT-qPCR) in 107 patients with NPM1 mutant AML enrolled in 
the UK National Cancer Research Institute (NCRI) AML17 study. After a median follow-up of 
4.9 years, patients with negative, low (<200 copies / 105 ABL in the PB and <1000 copies in 
the BM) and high levels of MRD had an estimated 2y overall survival (OS) of 83%, 63% and 
13% respectively (p<0.0001). Focussing on patients with low level MRD prior to alloSCT, 
those with FLT3 ITD had significantly poorer outcome (hazard ratio, HR, 6.14, p=0.01). 
Combining these variables was highly prognostic, dividing patients into two groups with 2y 
OS of 17% and 82% (HR 13.2, p<0.0001). 
 
T-depletion was associated with significantly reduced survival both in the entire cohort (2y 
OS 56% vs 96%, HR 3.24, p=0.0005) and in MRD positive patients (2y OS 34% vs 100%, 
HR 3.78, p=0.003) but there was no significant effect of either conditioning regimen or donor 
source on outcome.  
 







Optimal therapy for patients with cytogenetically normal acute myeloid leukaemia (AML) 
remains controversial, particularly regarding the use of allogeneic stem cell transplantation 
(alloSCT)1-3.  Many recent studies have identified the presence of measurable residual 
disease detected by polymerase chain reaction (PCR)4-10, flow cytometry (FCM)11-16 or next-
generation sequencing (NGS)17-19 as a powerful predictor of outcome and MRD status is 
increasingly used to allocate patients for transplantation20-23, however peri-transplant 
management of MRD positive patients remains highly challenging. 
 
Multiple studies have identified the presence of measurable residual disease (MRD) 
assessed by FCM24-32, abnormal gene expression33,34 and NGS35,36 immediately prior to 
alloSCT as a strong predictor of adverse outcome; patients who test positive using these 
methods have a relapse risk of up to 69%32.  As relapse after alloSCT carries a grave 
prognosis37 there is growing interest in peri-transplant interventions to reduce or eliminate 
MRD, which might diminish relapse risk31,38.  In this regard, the effect of different conditioning 
regimens on the outcome of patients who are MRD positive remains uncertain28,39,40. 
 
Although the great majority of studies of pre-transplant MRD in AML have utilised FCM, over 
half of patients with cytogenetically normal AML harbour mutations in the gene encoding 
nucleophosmin (NPM1)41,42. The recommended method for MRD assessment in these 
patients is reverse-transcription quantitative PCR (RT-qPCR)43 which affords a sensitivity of 
1:10-5  - 1:10-6 i.e. 100-1000 fold greater than that achieved by FCM or NGS4-10. Thus, the 
strongly adverse outcome reported in patients who are MRD positive using FCM and NGS 
may not be applicable to NPM1 mutated patients with low level positivity by PCR. Despite 
this, few studies have examined the impact of pre-transplant NPM1 MRD status44,45. 
Absence of robust outcome data for these patients is a barrier both to rational clinical 
decision making and to planning interventional studies in this setting. 
 
In this study, we report the outcomes of a large cohort of patients with NPM1 mutated AML 











Between 2009-2014 the NCRI AML17 study (ISRCTN 55675535) enrolled 3215 patients 
with non-M3 AML aged 16-77 eligible for intensive chemotherapy. The treatment protocol 
has been described previously46. Central screening for NPM1 mutations was positive in 
861/2949 (29%) and 530 of these provided serial samples for MRD monitoring. Paired blood 
(PB) and bone marrow aspirates (BM) were requested on regeneration after each cycle of 
chemotherapy and then every three months.  Post-remission treatment was determined 
according to the validated NCRI risk score, with poor-risk patients recommended for 
allogeneic stem-cell transplantation (alloSCT) during first complete remission (CR1).  Further 
information regarding calculation of the NCRI risk score is provided in the supplementary 
appendix.  For patients receiving a transplant, additional samples were requested prior to 
alloSCT, at D+30 and D+100 and then at three-monthly intervals for at least two years. For 
this study, pre-SCT results were included if the sample was taken within 60 days before 
transplant and the patient had not received any further therapy between sampling and the 
start of conditioning. Results were issued to treating clinicians from June 2012 only (i.e. 
51/107 patients) and after this time patients could be treated for confirmed re-emergent or 
persistent molecular positivity. 
 
Amplification of NPM1 mutated transcripts. 
 
Samples were analysed by RT-qPCR as previously described4.  Briefly, RNA was isolated 
using Trizol reagent (Life Technologies, Carlsbad, CA) and reverse transcribed using 
ThermoScript (Life Technologies).  Primer and probe sets described by Gorello et al7 were 
used to amplify NPM1 type A, B and D mutant transcripts and patient specific primers were 
designed to detect rare mutations. Samples were run in triplicate using an ABI 7900 
thermocycler (Life Technologies) with parallel amplification of a control gene (ABL). Samples 
with ABL cycle threshold of 30 were excluded. Criteria proposed by the Europe Against 
Cancer programme47 were used to define MRD positivity (i.e. amplification in at least two of 
three replicates with cycle-threshold values of 40 or less using a threshold setting of 0.1). 
Molecular relapse was diagnosed if there were two consecutive positive samples showing 
increasing transcript levels in a patient who had previously tested MRD negative in a 
technically adequate sample, consistent with ELN guidelines43. All NPM1 expression levels 
are reported as the number of mutated transcripts per 105 copies of ABL. 
 
 
Analysis of FLT3 ITD status and allelic ratio.  
 
PCR amplification of exons 14 and 15 of FLT3 was performed using fluorescently labelled 
primers and analysed using capillary electrophoresis as previously described48. The allelic 





Kaplan-Meier estimates were used to calculate survival percentages. Time to event analysis 
was performed using the log rank test. Thresholds were selected by identifying cut-offs 
providing the maximum discrimination between the low and high positive groups in terms of 
the hazard ratio for overall survival (supplementary figure 4). The threshold could not be 
zero and if a number of thresholds produced the same hazard ratio, the highest of these 
levels was selected. We used Cox regression with forward selection to identify independent 
prognostic factors. Categorical variables were analysed using Fisher’s exact test. All 




In total 107/ 530 patients received alloSCT: 56 (52%) in CR1, 30 (28%) after molecular 
relapse (MR) and 21 (20%) in second remission after morphological relapse (CR2) (figure 
1).  Clinical and molecular details are shown in table 1. Median follow-up was 4.9 years from 
transplant (range 1.0 – 8.4y). Forty-two (39%) patients died, the cause of death was disease 
relapse in 21 patients, was not attributed to relapse in 19 and could not be determined in 2 
patients.  Overall survival 2 years from the date of transplant (2y-OS) was 68% for patients 
transplanted in CR1 without molecular relapse, 63% for those transplanted after a molecular 
relapse and 57% for those in CR2 at the time of transplant. There were no statistically 
significant differences in survival between these groups (p=0.25 for CR1 vs others, p=0.63 
for molecular vs haematological relapse, p=0.22 for CR1 vs CR2, overall p=0.2 for trend, 
supplementary figure 1). 
 
Evaluable pre-SCT PB and BM samples taken in the 60 days preceding SCT were available 
for 103 and 78 patients, both were available for 74 patients.  The median time between 
sampling and transplant was 29 days (range 5-57 days). In total, 58 (54%) patients were 
MRD negative prior to SCT; 48 patients received additional chemotherapy prior to SCT for 
molecular (n=27) or haematological relapse (n=21) and 27/48 (56%) achieved MRD 
negativity (figure 1). 
 
Survival according to pre-transplant molecular MRD status 
 
Overall survival 2 years from allograft was 83% for MRD negative patients versus 45% for 
patients with any detectable MRD by RT-qPCR in the pre-transplant samples; median OS 
(mOS) was not reached (NR) and 10.5 months respectively (hazard ratio, HR, 3.60 95% 
confidence interval, CI, 1.92-6.77, p<0.0001, figure 2a). For patients with negative pre-SCT 
PB samples (n=73) 2y-OS was 81%, compared with 30% for patients with any PB positivity 
(n=30) (HR 8.30, CI 3.77-18.20, p<0.0001, fig 2b); mOS was NR and 7.4 months.  Patients 
with a negative pre-SCT BM (n=37) had a 5y-OS of 84% compared with 49% if the BM was 
MRD positive (n=41); mOS was NR and 13.1 months (HR 3.17, CI 1.54-6.54, p=0.002, 
figure 2c). 
 
For those patients who relapsed after transplant (n=21) the median time from relapse to 
death was 34 days (range 3-344 days, supplementary figure 2) and consequently overall 
and relapse-free survival times were similar. Relapse free survival curves are shown in 
supplementary figure 3. 
A threshold of 200 mutant NPM1 transcripts / 105 ABL copies in the pre-SCT PB sample 
provided maximum additional discrimination (supplementary figure 4) and split patients into 
three groups with 2y-OS of 81% (negative, n=73, mOS NR), 54% (low, 0.1-200 copies, 
n=13, mOS NR) and 12% (high, >200 copies, n=17, mOS 6.5 months, HR by group 2.81, CI 
1.96-4.02, p<0.0001, figure 2d, supplementary figure 3d). 
 
In the BM, a threshold of 1000 copies provided maximum additional discrimination 
(supplementary figure 4) and defined 3 groups with 2y-OS of 84% (negative, n=37, mOS 
NR), 56% (low, 0.1-1000 copies, n=32, mOS NR) and 22% (high, >1000 copies, n=9, mOS 
5.8 months, HR by group 2.87, CI 1.69-4.86, p<0.0001, figure 2e, supplementary figure 3e). 
 
Overall (applying the higher level where there was a discrepancy between PB and BM 
results), 2y-OS was 83% (n=58, mOS NR) 63% (n=30, mOS NR) and 13% (n=19, mOS 6.5 
months) for patients with negative, low and high levels of MRD (HR by group 2.83, CI 1.92-
4.19, p<0.0001, figure 2f, supplementary figure 3f). 
 
Impact of FLT3 status on post-transplant outcome 
 
We next stratified patients according FLT3 ITD status. Thirty-four patients were positive for 
FLT3-ITD at diagnosis and 73 were negative; 2y-OS was 62% and 67% respectively (HR 
1.14, CI 0.59-2.19, p=0.7).  FLT3 ITD status was not associated with outcome in patients 
who were MRD negative before transplant (2y-OS ITD negative 77%, n=40, ITD positive 
94%, n=18, HR 0.42, CI 0.14-1.28, p=0.13) or those who had high levels of MRD (2y-OS 
ITD negative 0%, n=11, ITD positive 25%, n=8, mOS 5.8 vs 6.8 months, HR 0.71 CI 0.26-
1.92, p=0.5). In contrast for patients with low levels of MRD, FLT3 ITD status was strongly 
associated with outcome: 2y-OS was 77% for ITD negative (n=22, mOS NR) and 25% for 
ITD positive patients (n=8, mOS 7.1 months, HR 6.14 CI 1.50-25.13, p=0.01, figure 3). 
 
Owing to small numbers (n=8), we were unable to reliably assess the effect of FLT3 ITD 
allelic ratio. Although a trend for better survival for patients with an allelic ratio <0.5 was 







Impact of first line post-induction MRD status on post-transplant outcome 
 
Peripheral blood MRD status after the second induction cycle of first line therapy (PBPC2) 
has previously been shown to be highly prognostic4 and retained power in this cohort (2y OS 
76% vs 33% for PBPC2 negative and positive patients, mOS NR vs 9.6 months, HR 4.93, CI 
2.05-11.90, p=0.0004). There was an association between PBPC2 and pre-SCT MRD 
negativity (p=0.002, table 1). Of those patients who were PBPC2 negative and experienced 
molecular or haematological relapse, 60% (21/35) achieved MRD negativity following 
salvage therapy and a further 14% (5/35) were MRD positive at levels below the thresholds 
defined above and were FLT3 WT; 2y OS for these patients was 88%. 
 
Multivariable model for prediction of post-transplant outcome 
 
We performed a multivariate analysis taking into account remission status at time of 
transplant (CR1 vs other), age at time of transplant, FLT3 ITD status, PBPC2 status and pre-
transplant MRD level (negative, low or high). The only factors which retained independent 
prognostic power were age (HR per decade 1.54, CI 1.08-2.19 p=0.02) and pre-transplant 
MRD level (HR 3.02, CI 1.97-4.62, p<0.0001). 
 
We developed a two-group prognostic model incorporating MRD status (negative, low or 
high) and FLT3 ITD (positive or negative). Patients who had high levels of MRD were 
allocated to the high-risk group together with patients with low levels of MRD who had FLT3 
ITD at diagnosis. The remaining patients were allocated to the low risk group. Patients with a 
negative PB and absent BM sample could not be reliably allocated to a risk group and were 
excluded from this analysis.  There was sufficient information to assign a risk group in 83 
patients. In the low-risk group (n=56) 2y-OS was 82% compared to 17% in the high-risk 
group (n=27, mOS NR vs 6.5 months, HR 13.2, CI 5.80-30.2, p<0.0001, figure 4, 
supplementary figure 6). 
 
When risk group (low or high) was introduced as a candidate variable into the multivariable 
model described above, the only factors to retain prognostic significance were age at time of 






Effect of transplant-related factors on outcome according to MRD status 
 
Donor source was a matched sibling in 43 patients, a volunteer unrelated donor (VUD) in 63 
and umbilical cord blood in 1. Although a trend for greater overall survival in patients whose 
donor was a sibling compared to a VUD was noted, this was not statistically significant (2y-
OS 72% vs 62%, HR 1.81, CI 0.97-3.35, p=0.06, figure 5a). 
 
Conditioning regimens were considered myeloablative (MAC) in 30 patients (28%, BuCy 4, 
CyTBI 20, FB4C 6) and reduced-intensity (RIC) in 77 (72%, FluMel 48, FluBu 11, FLAMSA-
Bu 8, FluTBI 6, FluCy 2, FluCyTBI 2). Patients who received MAC were significantly younger 
(mean 43 vs 56 years p<0.0001).  There was no difference in overall survival according to 
conditioning regimen type (2y OS MAC 71%, RIC 63%, HR 1.18, CI 0.61-2.29, p=0.6, figure 
5b). 
 
Alemtuzumab was given to 70 (65%) and anti-thymocyte globulin (ATG) to 12 (11%) patients 
for T-depletion; 2y-OS was 56% for these patients with no difference by T-depletion agent, 
compared to 96% in patients who did not receive T-depletion (n=25, HR 3.24, CI 1.69-6.42, 
p=0.0005, figure 5c).  Patients who received T-depletion were older (mean 54 vs 47y, 
p=0.0028) and were more likely to have been transplanted using a VUD (67% vs 33% for 
non-T-depleted, p=0.004) and with RIC (80% vs 44% for non-T depleted, p=0.0008).  
Cumulative incidence of relapse at 5 years was 24% in patients who underwent T-depletion 
compared with 4% in those who did not (p=0.0149). Cumulative incidence of non-relapse 
mortality at 5 years was 23% in patients who underwent T-depletion compared with 4% in 
patients who did not (p=0.0148). 
 
Considering patients who were MRD positive prior to allograft, there was a trend for lower 
OS in patients who had received a VUD transplant (2y-OS 38% vs 55% for SIB, HR 1.94, CI 
0.92-4.08, p=0.08, figure 5d). There was no association between OS and type of 
conditioning (2y OS 50% for MAC vs 43% for RIC, HR 1.22, CI 0.54-2.76, p=0.6, figure 5e). 
Specifically, MRD positive patients treated with the sequential FLAMSA protocol had no 
difference in overall survival.  Patients who were MRD positive and who received T-depletion 
showed inferior overall survival than those who did not (2y-OS 34% vs 100%, mOS 7.8m vs 







Patients with NPM1 mutated AML who test MRD negative by RT-qPCR prior to transplant 
have an excellent chance of long-term survival regardless of other risk factors including 
FLT3 status and independent of the intensity of the transplant conditioning regimen. 
 
As expected, NPM1 MRD positivity had an overall adverse effect on transplant outcome, but 
in contrast to patients who are MRD positive by FCM or NGS, patients who test positive for 
NPM1 mutant transcripts prior to alloSCT do not have a universally poor outcome, indeed 
many become long-term survivors.  Factors associated with adverse outcome are high 
levels of MRD (above 200 copies / 105 ABL in the PB or 1000 copies in the BM) and the 
presence of a FLT3 ITD mutation at diagnosis. Patients who are MRD positive before 
transplant and have one or both of these features have a poor prognosis due to a high risk 
of disease relapse. Our data do not exclude the possibility that MRD positive patients with a 
low FLT3 ITD allelic ratio may have a somewhat better outcome and larger studies will be 
required to address this. 
 
Interestingly the threshold we identified of 1000 copies / 105 ABL in the bone marrow is the 
same as that selected by Kayser and colleagues45 for their study of 39 patients with NPM1 
mutated AML in first or second morphological complete remission prior to transplant.  In that 
study, the outcomes of patients with levels exceeding the threshold was the same as 
patients who were not in remission. No effect of either FLT3 ITD status or allelic ratio was 
identified however we speculate that this may have been due to the sample size and indeed 
the only relapse observed in the group with MRD levels below the threshold was in a patient 
with FLT3 ITD which would be consistent with our findings.  Bill and colleagues46 also report 
a significant difference in outcome according to molecular MRD status in 51 patients with 
NPM1 mutated AML.  In this study a lower threshold equivalent to 10 copies / 105 ABL was 
selected based on the technical characteristics of the digital droplet PCR platform employed, 
however this was applied to both PB and BM samples, and alternative cut-off levels were not 
comprehensively evaluated. Comparative studies of these two highly sensitive platforms 
would be of great interest. 
 
Shayegi and colleagues10 identified post-transplant MRD levels equivalent to 10,000 copies / 
105 ABL as strongly predictive of relapse. In the present study we did not investigate post-
transplant MRD levels as these were not available for all patients, however approximately 
half of patients had post-transplant MRD results provided to their treating physician and 
these were used to inform interventions such as immunosuppressive therapy and donor 
lymphocyte infusion. These manipulations may have affected the outcome for some patients 
and it is possible that they reduced the overall survival difference between the MRD positive 
and negative groups. Nevertheless, we did not observe a difference in overall survival 
between patients who did or did not have post-transplant results returned (data not shown). 
 
In this study 27/48 (56%) of patients with a haematological or confirmed molecular relapse 
achieved MRD negativity with salvage chemotherapy and a further 8/48 (17%) became low 
risk as defined in our risk score. These 35 patients had an excellent outcome with an overall 
survival of 80% at 2 years.  Additionally, 74% of patients who tested negative for MRD in the 
PB after second induction (PBPC2) and who subsequently relapsed achieved MRD 
negativity or low-risk status after salvage and had a 2y OS of 88%. This supports the 
approach adopted in the current NCRI AML19 protocol where such patients are not 
recommended for transplantation in CR1 and are offered sequential MRD monitoring to 
allow early detection and treatment of relapse. 
 
Selection of transplant protocol remains controversial, particularly for patients who are MRD 
positive, and a key question is whether augmented conditioning can eliminate MRD and 
thereby improve outcome.  Studies to date have provided conflicting results and have not 
examined the effect of transplant related factors specifically in NPM1 mutated 
patients28,39,40,49.  Surprisingly, we observed no effect on survival according to conditioning 
type, either overall or in patients who were MRD positive. In contrast, we observed a strong 
association between use of T-depletion and adverse outcome.  Relatively few patients who 
were MRD positive received T-replete transplants (n=8) and this retrospective non-
randomised analysis clearly has significant limitations, however these results highlight T-
depletion as a potentially critical factor which has not been consistently reported in other 
studies to date. 
 
These findings require independent validation, however patients at highest risk of relapse 
identified here may benefit from an alternative approach prior to transplant such as the use 
of FLT3 inhibition to reduce the level of MRD below the thresholds identified. Alternatively, 
augmentation of the graft-versus-leukaemia effect (e.g. through avoidance or minimisation of 
T-depletion, early withdrawal of immunosuppression and / or donor lymphocyte infusion) 
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Clinical, molecular and transplant-related variables in each MRD-defined group.  Spearman 
correlation p value is provided for the age comparison and Mantel-Haenszel p value is provided for all 

























FLT3 ITD positive 8 (42%) 8 (27%) 18 (31%) 0.5 
FLT3 ITD allelic ratio >0.5 4 (21%) 3 (10%) 7 (12%) 0.4 
PB Post #2 MRD positive 6/17 (35%) 11/26 (42%) 4/53 (8%) 0.002 
Transplanted in CR1 5 (26%) 20 (67%) 31 (53%) 0.16 
Myeloablative conditioning 8 (42%) 6 (20%) 17 (29%) 0.5 
Sibling donor 6 (32%) 14 (47%) 23 (40%) 0.7 




















Figure 1.  
CONSORT diagram showing the number of patients in each part of the trial, therapy given 
prior to transplant and outcomes in each group. CT chemotherapy, MRD measurable residual 
disease, NRM non-relapse mortality, REL relapse, UNK unknown cause of death. 
 
Figure 2. 
Overall survival from date of transplant according to pre-transplant molecular MRD status. 
Panels A-C show the difference in survival between patients with positive and negative MRD (A) 
overall (B) in the peripheral blood, (C) in the bone marrow. Panels D-F show the difference in survival 
between patients with negative, low and high levels of MRD (D) in the peripheral blood using a cut-off 
at 200 copies per 10
5
 ABL (E) in the bone marrow with level of >1000 copies and (E) with either, 
defining “high level” MRD. Percentages indicate estimated 2 year OS. 
 
Figure 3.  
Effect of FLT3 ITD on outcome according to pre-transplant MRD status. (A) Hazard ratio and 
95% confidence intervals for FLT3 ITD mutation in each group. (B-D) Overall survival from transplant 
for patients with high (B), low (C) and negative (D) pre-transplant MRD. Percentages indicate 
estimated 2 year overall survival. 
 
Figure 4.  
Overall survival from transplant according to the risk group. The risk group was derived from 
FLT3 ITD status and pre-transplant MRD level. Patients with high levels of MRD, and those with low 
levels who had the FLT3 ITD mutation were allocated to the high-risk group. All other patients were 
allocated to the low-risk group. Percentages indicate estimated 2 year overall survival. 
 
Figure 5.  
Effect of transplant-related factors on overall survival. Panels A-C show the effect of transplant 
related variables in the entire cohort, panels D-F show their effect in patients who were MRD-positive 
prior to transplantation. (A,D) Effect of donor source. (B,E) Effect of conditioning type. (C,F) Effect of 
T-cell depletion. SIB sibling donor, VUD volunteer unrelated donor, MAC myeloablative conditioning, 
RIC reduced intensity conditioning. 
 
3215 non APL patients 
2949 screened for NPM1 266 not screened 
861 NPM1 mutated   (29%) 2088 NPM1 wild type 
530 provided MRD samples   (62%) 331 did not provide samples 
56 transplanted in CR1 474 not transplanted in CR1 
30 transplanted for  
molecular relapse 
21 transplanted for 
morphological relapse 
423 never transplanted 
21 had salvage CT 27 had salvage CT 3 no salvage CT 
3 MRD+ 11 MRD+ 16 MRD- 10 MRD+ 11 MRD- 25 MRD+ 31 MRD- 
6 died 
NRM = 6 
REL = 0 
UNK = 0 
13 died 
NRM = 4 
REL = 9 
UNK = 0 
7 died 
NRM = 2 
REL = 4 
UNK = 1 
4 died 
NRM = 2 
REL = 2 
UNK = 0 
7 died 
NRM = 0 
REL = 6 
UNK = 1 
4 died 
NRM = 4 
REL = 0 
UNK = 0 
1 died 
NRM = 1 
REL = 0 
UNK = 0 
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